KR102561721B1 - 비펩티드성 옥시토신 수용체 작용제 - Google Patents

비펩티드성 옥시토신 수용체 작용제 Download PDF

Info

Publication number
KR102561721B1
KR102561721B1 KR1020197019977A KR20197019977A KR102561721B1 KR 102561721 B1 KR102561721 B1 KR 102561721B1 KR 1020197019977 A KR1020197019977 A KR 1020197019977A KR 20197019977 A KR20197019977 A KR 20197019977A KR 102561721 B1 KR102561721 B1 KR 102561721B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
alkyl
alkynyl
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197019977A
Other languages
English (en)
Korean (ko)
Other versions
KR20190091534A (ko
Inventor
미카엘 카씨우
윌리엄 요르겐센
에린 웨리
트리스탄 리키
미카엘 보웬
이언 맥그레고르
Original Assignee
키녹시스 테라퓨틱스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by 키녹시스 테라퓨틱스 피티와이 리미티드 filed Critical 키녹시스 테라퓨틱스 피티와이 리미티드
Publication of KR20190091534A publication Critical patent/KR20190091534A/ko
Application granted granted Critical
Publication of KR102561721B1 publication Critical patent/KR102561721B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020197019977A 2016-12-12 2017-12-12 비펩티드성 옥시토신 수용체 작용제 Active KR102561721B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists
AU2016905126 2016-12-12
PCT/AU2017/051371 WO2018107216A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Publications (2)

Publication Number Publication Date
KR20190091534A KR20190091534A (ko) 2019-08-06
KR102561721B1 true KR102561721B1 (ko) 2023-07-28

Family

ID=62557695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019977A Active KR102561721B1 (ko) 2016-12-12 2017-12-12 비펩티드성 옥시토신 수용체 작용제

Country Status (19)

Country Link
US (2) US11491165B2 (https=)
EP (2) EP4494705A3 (https=)
JP (3) JP7089649B2 (https=)
KR (1) KR102561721B1 (https=)
CN (1) CN110248944A (https=)
AU (1) AU2017377653B2 (https=)
BR (1) BR112019012049A2 (https=)
CA (1) CA3046809A1 (https=)
DK (1) DK3551631T3 (https=)
ES (1) ES3001195T3 (https=)
FI (1) FI3551631T3 (https=)
HU (1) HUE070078T2 (https=)
IL (1) IL267276B2 (https=)
MX (1) MX2019006942A (https=)
PL (1) PL3551631T3 (https=)
PT (1) PT3551631T (https=)
RU (1) RU2019120162A (https=)
SI (1) SI3551631T1 (https=)
WO (1) WO2018107216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500317A (ja) 2001-06-25 2005-01-06 フェリング ベスローテン フェンノートシャップ オキシトシンアゴニスト
JP2005501858A (ja) 2001-08-16 2005-01-20 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬としてのジアザシクロアルカン
WO2006021213A2 (en) 2004-08-24 2006-03-02 Ferring B.V. Vasopressin v1a antagonists
JP2006517530A (ja) * 2003-02-14 2006-07-27 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
JP2007504263A (ja) 2003-09-05 2007-03-01 フェリング ベスローテン フェンノートシャップ オキシトシン作働薬としてのピペラジン類

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US7342112B2 (en) * 2003-07-01 2008-03-11 Ppg Industries Ohio, Inc. Photochromic compounds
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
AU2006306547A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
WO2008103382A1 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
US10508108B2 (en) * 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
PL3328864T3 (pl) * 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500317A (ja) 2001-06-25 2005-01-06 フェリング ベスローテン フェンノートシャップ オキシトシンアゴニスト
JP2005501858A (ja) 2001-08-16 2005-01-20 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬としてのジアザシクロアルカン
JP2006517530A (ja) * 2003-02-14 2006-07-27 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
JP2007504263A (ja) 2003-09-05 2007-03-01 フェリング ベスローテン フェンノートシャップ オキシトシン作働薬としてのピペラジン類
WO2006021213A2 (en) 2004-08-24 2006-03-02 Ferring B.V. Vasopressin v1a antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem. 2010, 53, pp. 1546-1562.*

Also Published As

Publication number Publication date
CN110248944A (zh) 2019-09-17
US20200000823A1 (en) 2020-01-02
IL267276B1 (en) 2024-05-01
BR112019012049A2 (pt) 2019-11-12
EP3551631A1 (en) 2019-10-16
AU2017377653B2 (en) 2022-04-21
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2022097655A (ja) 2022-06-30
RU2019120162A (ru) 2021-01-12
ES3001195T3 (es) 2025-03-04
PL3551631T3 (pl) 2025-03-24
HUE070078T2 (hu) 2025-05-28
IL267276B2 (en) 2024-09-01
DK3551631T3 (en) 2025-02-17
US20230330103A1 (en) 2023-10-19
CA3046809A1 (en) 2018-06-21
MX2019006942A (es) 2019-10-21
EP3551631B1 (en) 2024-11-13
FI3551631T3 (fi) 2025-01-16
EP4494705A3 (en) 2025-04-02
EP3551631B9 (en) 2025-02-26
JP2020500924A (ja) 2020-01-16
US11491165B2 (en) 2022-11-08
RU2019120162A3 (https=) 2021-01-28
WO2018107216A1 (en) 2018-06-21
IL267276A (en) 2019-08-29
PT3551631T (pt) 2024-12-10
SI3551631T1 (sl) 2025-03-31
AU2017377653A1 (en) 2019-07-11
KR20190091534A (ko) 2019-08-06
EP4494705A2 (en) 2025-01-22
JP7089649B2 (ja) 2022-06-23
NZ754890A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
KR102561721B1 (ko) 비펩티드성 옥시토신 수용체 작용제
JP6382403B2 (ja) Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3828174A1 (en) Pyridazinone derivative
UA47396C2 (uk) N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання та фармацевтична композиція на їх основі (варіанти), спосіб її одержання та спосіб лікування нейрогенного запалення
DE19963868A1 (de) Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR20200014894A (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
AU2019247842B2 (en) Opioid receptor modulators and products and methods related thereto
NZ241597A (en) Imidazopyridine paf/h 1 antagonists
CA3253487A1 (en) MULTICYCLICAL COMPOUNDS
US5330994A (en) Tetrahydropyridine isoxazoline derivatives
CA2112083C (en) Aryl substituted heterocyclic compounds
KR20230022861A (ko) Tead 결합제로서 유용한 트리시클릭 헤테로사이클
US20240208907A1 (en) Gpr52 modulators and methods of use
EP4200299B1 (en) Compounds for prevention or treatment of neurodegenerative disorders
HK40014275A (en) Non-peptide oxytocin receptor agonists
HK40053244A (en) Pyridazinone derivative
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
NZ717556B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190710

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200924

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20211125

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221121

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230427

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230726

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230726

End annual number: 3

Start annual number: 1

PG1601 Publication of registration